Summary: Journalist Mike Riggs of Reason discusses MAPS’ upcoming Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD on The Cato Institute’s Daily Podcast. “Phase 3 clinical trials are basically the last step before drug approval and they can take a few years. And that is where you’re taking a really, big sample size and in MAPS case they are looking at doing something around 240 or 250 patients who have anxiety as a result of their PTSD. And they are going across 14 different clinical sites with many different groups of therapists,” explains Riggs.
Originally appearing here.
The drug MDMA – also known as ecstasy – is now entering Phase III trials as part of the FDA approval process for use as a treatment. How did we get here? Mike Riggs of Reason tells the story.